Cytokine interest shows no sign of waning
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
Amgen doubles down on bispecifics, courtesy of Teneobio
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
Ash 2020 – IGM averts disaster, but competition looms
Sellside firefighting has saved the day for IGM, but Ash hears of some pretty potent anti-CD20 competition for the company.
SITC 2020 – embargo snafu triggers the first movers
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Esmo 2020 – more encouraging signs for checkpoint bispecifics
Promising but early data on PD-1 x CTLA-4 bispecifics from Macrogenics and Akeso add further weight to this approach.
